- Cytel's carbohydrate-based selectin blocker, Cylexin, appears to reduce reperfusion injury after surgical removal of blood clots from the lungs, according to the results of a Phase II trial involving 51 patients. The drug is also being evaluated for its ability to reduce reperfusion injury after angioplasty and thrombolytic therapy after a heart attack.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze